Scarica l'app Stockscreener
1.83
8.04%
-0.16
Dopo l'orario di chiusura:
1.89
0.06
+3.28%
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Mainz Biomed (NASDAQ:MYNZ) Trading Down 1.9% – Here’s What Happened - Defense World
(MYNZ) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Ca - GuruFocus
Mainz Biomed Initiates Feasibility Study Of PancAlert Blood Test For Pancreatic Cancer Detection - Nasdaq
Mainz Biomed Initiates Feasibility Study Of Biomarker Panel In Pancreatic Cancer Project - marketscreener.com
Mainz Biomed (MYNZ) Advances PancAlert Project for Pancreatic Cancer Detection | MYNZ Stock News - GuruFocus
Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project - Nasdaq
Mainz initiates feasibility study of biomarker panel in PancAlert project - TipRanks
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project - GlobeNewswire
Revolutionary Blood Test Detects Pancreatic Cancer with 95% Accuracy, Mainz Biomed Study Reveals - Stock Titan
Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting - TipRanks
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | M - GuruFocus
Mainz Biomed N.V. Secures $4 Million Through Securities Offering - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Trading Up 5.4% – What’s Next? - Defense World
Mainz Biomed (MYNZ) Prices $4M Follow-On Offering - GuruFocus
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | MYNZ Stock News - GuruFocus
Mainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant Amendments - Nasdaq
Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com Nigeria
Trend Tracker for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed to update on CRC screening study by end of summer - Investing.com South Africa
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Mainz Biomed Plans Interim Readout For EAArly DETECT 2 CRC Study - Nasdaq
Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan
MYNZ Stock Update: Maxim Group's Role as Manager | MYNZ Stock News - GuruFocus
Mainz Biomed to hold annual meeting on June 2 - Investing.com Australia
Mainz Biomed to hold annual meeting on June 2 By Investing.com - Investing.com Canada
Mainz Biomed Prepares for June 2025 Annual General Meeting - TipRanks
Stocks of Mainz Biomed N.V (MYNZ) are poised to climb above their peers - Sete News
Investing in Mainz Biomed N.V (MYNZ): What You Must Know - knoxdaily.com
Mainz Biomed Enters into Technology Partnership with EDX Medical Group - MSN
MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus
Strategic Partnership: Mainz Biomed and EDX Medical Join Forces to Transform Early Cancer Detection in UK Market - Stock Titan
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for Co - GuruFocus
Mainz Biomed N.V (NASDAQ: MYNZ) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
Mainz Biomed advances in FDA approval for CRC test By Investing.com - Investing.com South Africa
Mainz Biomed advances in FDA approval for CRC test - Investing.com Australia
The Mainz Biomed N.V (MYNZ) Stock Is Headed for a Correction - uspostnews.com
MYNZ: Mainz Biomed Advances Cancer Detection with New Feasibilit - GuruFocus
Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire
Mainz Biomed's Game-Changing Cancer Test Shows 98% Accuracy as Company Expands European Presence - Stock Titan
Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 48.7% in April - Defense World
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
0.65%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):